Sugi Predict

Sugi Predict / Compounds / SCHEMBL164053

SCHEMBL164053

SCHEMBL164053

O=c1[nH]cnc2cc(O)c(O)cc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 10/20 0.62
▸ BCL2 P10415 1/20 0.58
▸ MCL1 Q07820 1/20 0.58
▸ CHEK1 O14757 2/20 0.53
▸ PIM1 P11309 2/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ AKT1 P31749 1/20 0.53
▸ FLT3 P36888 1/20 0.53
▸ PIM3 Q86V86 1/20 0.53
▸ RPS6KA3 P51812 1/20 0.53
▸ MKNK1 Q9BUB5 1/20 0.51
▸ SLC2A1 P11166 1/20 0.51
▸ PDPK1 O15530 1/20 0.50
▸ CA12 O43570 1/20 0.50
▸ ALOX15 P16050 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ CA9 Q16790 1/20 0.50
▸ TNKS2 Q9H2K2 1/20 0.50
▸ IP6K1 Q92551 4/20 0.49
▸ KDM4A O75164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14520677 0.85 PARP1 (0.56) PARP1BCL2MCL1CHEK1PIM1
SCHEMBL10121484 0.85 PARP1 (0.56) PARP1BCL2MCL1CHEK1PIM1
SCHEMBL12788028 0.83 PARP1 (0.53) PARP1BCL2MCL1CHEK1PIM1
SCHEMBL12304877 0.83 PARP1 (0.53) PARP1BCL2MCL1CHEK1PIM1
SCHEMBL641721 0.81 SRC (0.54) PARP1BCL2MCL1CHEK1PIM1
SCHEMBL298221 0.81 PARP1 (0.51) PARP1BCL2MCL1CHEK1PIM1
Hydrochloric Acid SCHEMBL27988354 0.80 SRC (0.52) PARP1BCL2MCL1CHEK1PIM1
SCHEMBL4371996 0.80 PARP1 (0.56) PARP1BCL2MCL1CHEK1PIM1
SCHEMBL4490582 0.79 PARP1 (0.49) PARP1BCL2MCL1CHEK1PIM1
SCHEMBL3240833 0.79 PARP1 (0.49) PARP1BCL2MCL1CHEK1PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120058675-A Preparation and purification method and application of quinoline derivative with biological activity 河南科技大学 2025-05-30 — — CN claimed
CN-120058675-A Preparation and purification method and application of quinoline derivative with biological activity 河南科技大学 2025-05-30 — — CN disclosed
US-20180050993-A1 NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS TRILLIUM THERAPEUTICS INC. (CA) 2018-02-22 — — US disclosed
US-20180050993-A1 NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS TRILLIUM THERAPEUTICS INC. (CA) 2018-02-22 — — US disclosed
US-20180050993-A1 NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS TRILLIUM THERAPEUTICS INC. (CA) 2018-02-22 — — US disclosed
CN-107652310-A The cephem compounds of 2 substitutions 葛兰素集团有限公司 2018-02-02 — — CN disclosed
EP-3012251-B1 PROCESS FOR THE PREPARATION OF 6,7-DIALKOXY QUINAZOLINE DERIVATIVES NATCO PHARMA LTD (IN) 2017-08-30 — — EP disclosed
EP-3015460-B1 PROCESS FOR THE PREPARATION OF ERLOTINIB CERBIOS-PHARMA S A (CH) 2017-05-17 — — EP disclosed
US-20170079983-A1 6,7-DIALKOXY QUINAZOLINE DERIVATIVES AND METHODS OF TREATING DRUG RESISTANT AND OTHER TUMORS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2017-03-23 — — US disclosed
US-9549988-B2 Pharmaceutical compounds targeted by MIF affinity-tethered moieties RJS Biologics (US) 2017-01-24 — — US disclosed
US-20070287707-A1 Phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-12-13 — — US disclosed
US-20070265258-A1 Quinazoline derivatives as phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 — — US disclosed
WO-2007103370-A2 QUINAZOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-09-13 — — WO disclosed
WO-2007100880-A1 CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-09-07 — — WO disclosed
WO-2007060691-A2 A NOVEL PROCESS FOR THE PREPARATION OF ERLOTINIB NATCO PHARMA LIMITED (IN) 2007-05-31 — — WO disclosed
US-20070093515-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-04-26 — — US disclosed
US-20070093515-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-04-26 — — US disclosed
US-20070093515-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-04-26 — — US disclosed
WO-2007022280-A1 PHOSPHODIESTERASE 10 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2007-02-22 — — WO disclosed
WO-2007022280-A1 PHOSPHODIESTERASE 10 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2007-02-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180050993-A1 NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS EGFR, ERBB2, ERBB4 PARP1 1966/4885BCL2 1018/4885MCL1 27/4885
US-20070093515-A1 Phosphodiesterase 10 inhibitors PDE7A, PDE12, PDE10A PARP1 1264/4885BCL2 3295/4885MCL1 2347/4885
US-20070287707-A1 Phosphodiesterase 10 inhibitors PDE7A, PDE7B, PDE10A PARP1 591/4885BCL2 3973/4885MCL1 2445/4885
US-20070265258-A1 Quinazoline derivatives as phosphodiesterase 10 inhibitors PDE12, PDE5A, PDE7A PARP1 809/4885BCL2 4005/4885MCL1 2291/4885
US-20170079983-A1 6,7-DIALKOXY QUINAZOLINE DERIVATIVES AND METHODS OF TREATING DRUG RESISTANT AND OTHER TUMORS ERBB2, EGFR, STK17A PARP1 3284/4885BCL2 2433/4885MCL1 1724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.